Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Pierre Van Damme, Anna Moiseeva, Igor Marichev, Anne-Diane Kervyn, Robert Booy, Sherine Kuriyakose, Andrew Brockway, Su-Peing Ng, Maarten Leyssen, Jeanne-Marie Jacquet, Pierre Van Damme, Anna Moiseeva, Igor Marichev, Anne-Diane Kervyn, Robert Booy, Sherine Kuriyakose, Andrew Brockway, Su-Peing Ng, Maarten Leyssen, Jeanne-Marie Jacquet

Abstract

Background: The standard three-dose schedule of hepatitis B vaccines is frequently not completed, especially in adolescents. A primary study has confirmed the equivalence of a two-dose schedule of an Adult formulation of hepatitis B vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in adolescents (11-15 years) [Group HBV_3D]. This follow-up study evaluated the five year persistence of antibody response and immune memory against the hepatitis B surface (anti-HBs) antigens five years after completion of primary vaccination.

Methods: A total of 234 subjects returned at the Year 5 time point, of which 144 subjects received a challenge dose of hepatitis B vaccine. Blood samples were collected yearly and pre- and post-challenge dose to assess anti-HBs antibody concentrations.

Results: At the end of five years, 79.5% (95% confidence interval [CI]: 71.7 - 86.1) and 91.4% (95% CI: 82.3 - 96.8) of subjects who received the two-dose and three-dose schedules, respectively had anti-HBs antibody concentrations ≥ 10 mIU/mL. Post-challenge dose, all subjects had anti-HBs antibody concentration ≥ 10 mIU/mL and >94% subjects had anti-HBs antibody concentration ≥ 100 mIU/mL. All subjects mounted a rapid anamnestic response to the challenge dose. Overall, the challenge dose was well-tolerated.

Conclusion: The two-dose schedule of hepatitis B vaccine confers long-term immunogenicity and shows evidence of immune memory for at least five years following vaccination.

Trial registration: Clinical Trials NCT00343915, NCT00524576.

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
Percentage of subjects with anti-HBs concentration ≥10 mIU/mL at all long-term follow-up time points (Long-term ATP cohort for immunogenicity).
Figure 3
Figure 3
Evolution of anti-HBs antibody geometric mean concentrations (GMCs) during the five years follow-up period (Long-term ATP cohort for immunogenicity) and during the challenge phase (ATP cohort for immunogenicity).

References

    1. World Health Organization (WHO) Position paper on Hepatitis B. Wkly Epidemiol Rec. 2009;84:405–420.
    1. Gold Y, Somech R, Mandel D, Peled Y, Reif S. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. Acta Paediatrica. 2003;92:1158–1162. doi: 10.1111/j.1651-2227.2003.tb02477.x.
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hep. 2004;11:97–107. doi: 10.1046/j.1365-2893.2003.00487.x.
    1. Heron L, Selnikova O, Moiseieva A, Van Damme P, Van der Wielen M, Levie K, Hoet B, Stoffel M. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: A randomised controlled trial. Vaccine. 2007;25:2817–2822. doi: 10.1016/j.vaccine.2006.12.021.
    1. Centers for Disease Control and Prevention (CDC) Global progress toward universal childhood hepatitis B vaccination. MMWR Morb Mort Wkly Rep. 2003;52:868–870.
    1. Kottenhahn RK, Rosenthal SL, Biro FM. Hepatitis B vaccine completion among adolescents. Del Med J. 1996;68:309–311.
    1. Middleman AB, Robertson LM, Young C, Durant RH, Emans SJ. Predictors of time to completion of the hepatitis B vaccination series among adolescents. J Adolesc Health. 1999;25:323–327. doi: 10.1016/S1054-139X(99)00063-4.
    1. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine. 2002;20:3472–3476. doi: 10.1016/S0264-410X(02)00346-8.
    1. González IM, Averhoff FM, Massoudi MS, Yusuf H, DeStefano F, Kramarz P, Maher JE, Mullooly JP, Chun C, Davis RL, Black SB, Shinefield HR. Vaccine Safety Datalink Team. Hepatitis B vaccination among adolescents in 3 large health maintenance organizations. Pediatrics. 2002;110:929–934.
    1. Australian immunisation handbook, Section 3.9 Hepatitis B. 9. 2008. Accessed: 20 January, 2010.
    1. Van der Sande MAB, Mendy M, Waight P, Doherty C, McConkey SJ, Hall AJ, Whittle HC. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine. 2007;25:1509–1512. doi: 10.1016/j.vaccine.2006.10.023.
    1. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021–1051. doi: 10.2165/00003495-200363100-00006.
    1. Gabbuti A, Romano L, Blanc P, Meacci F, Amendola A, Mele A, Mazzotta F, Zanetti AR. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007;25:3129–3132. doi: 10.1016/j.vaccine.2007.01.045.
    1. Cambron P, Jacquet JM, Hoet B, Lievens M. Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin Vaccine Immunol. 2009;16:1236–1246. doi: 10.1128/CVI.00431-08.
    1. Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A Randomized Trial of Alternative Two- and Three-Dose Hepatitis B Vaccination Regimens in Adolescents: Antibody Responses, Safety, and Immunologic Memory. Pediatrics. 2001;107:626–631. doi: 10.1542/peds.107.4.626.
    1. Faustini A, Franco E, Sangalli M, Spadea T, Calabrese RM, Cauletti M, Perucci CA. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine. 2000;19:2812–2818. doi: 10.1016/S0264-410X(01)00005-6.
    1. Duval B, Gîlca V, Boulianne N, De Wals P, Masse R, Trudeau G, De Serres G. Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country. Pediatr Infect Dis J. 2005;24:213–218. doi: 10.1097/01.inf.0000154329.00361.39.
    1. Van Damme P, Von Sonnenburg F, Hatz C, Hoet B, Lefevre I, Leyssen M. Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. J Med Virol. 2009;81:1710–1715. doi: 10.1002/jmv.21568.
    1. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, Trivello R. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine. 2007;22:607–610.
    1. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2001;19:877–885. doi: 10.1016/S0264-410X(00)00224-3.
    1. Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, Montù D, Tozzi AE, D'Ancona F. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis. 2010. in press .
    1. Levie K, Beran J, Collard F, Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine. 2002;20:2579–2584. doi: 10.1016/S0264-410X(02)00153-6.
    1. Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix™) in adults. Travel Med and Infect Dis. 2007;5:171–175. doi: 10.1016/j.tmaid.2006.07.003.
    1. Roberton D, Marshall H, Nolan TM, Sokal E, D'ıez-Domingo J, Flodmark E. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children. Vaccine. 2005;23:5099–5105. doi: 10.1016/j.vaccine.2005.06.003.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться